Zeus Capital has acted as nominated adviser and sole broker to C4X Discovery on its successful AIM IPO and £11 million fundraise. On admission, C4X Discovery had a market capitalisation of £31 million.
C4X Discovery is a Manchester-based company focused on optimising drug discovery and design. Founded in 2008 as a spin-out from the University of Manchester, the company uses its NMR-based technology in collaboration with the pharmaceutical industry to solve the dynamic 3D structures of a broad range of biomolecules.
As well as this, C4X Discovery has the only technology in the world that can generate accurate, experimentally- derived dynamic solution 3D structures of drug molecules in just a matter of days. The technology can also be applied to help identify and generate novel crystal polymorph forms, with exciting potential applications in the life cycle management of existing branded pharmaceuticals.
Dominic Wilson, Director of Healthcare at Zeus Capital commented:
“We are proud to have been involved in the IPO of C4X Discovery. The management team has substantial experience in the analysis and design of three dimensional molecular structures with applications in the pharmaceutical industry. We believe C4X Discovery has a world-beating and disruptive technology platform. The funds raised will enable the company to take forward two of its drug development candidates as well as bring in new partners within big pharma. We look forward to following the company’s progress.”